{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:08:19Z","timestamp":1794978499869,"version":"4.9.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Obesity, which currently affects over one billion individuals, is widely recognised as a global condition. It is strongly associated with an increased incidence of cardiovascular disease (CVD), which accounts for 26.8% of all deaths worldwide. The emergence of new anti-obesity medications that can provide greater weight loss and more significant clinical benefits has underscored the urgent need for structured guidelines that integrate obesity treatment into CVD prevention strategies. This article, developed through a collaboration among five leading Brazilian medical societies (Brazilian Association for the Study of Obesity and Metabolic Syndrome, Brazilian Diabetes Society, Brazilian Society of Endocrinology and Metabolism, Brazilian Cardiology Society, and Brazilian Sleep Academy), aims to structure obesity treatment within the context of CVD prevention, considering both cardiovascular risk and obesity stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Delphi method was used to develop the guideline by engaging a panel of twenty experts who formulated 25 evidence-based recommendations through multiple rounds of structured voting. Each recommendation was designed to address specific clinical scenarios and assigned a recommendation grade based on statistical analysis consensus levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following cardiovascular risk assessment using the Predicting Risk of CVD Events risk score, individuals with obesity or overweight will be stratified according to their 10-year risk of developing atherosclerotic disease (low, moderate, or high) and heart failure (high-risk). Anti-obesity treatment will then be guided by the best evidence-based recommendations designed to address excess adiposity and reduce associated complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This guideline offers a practical, evidence-based framework for the treatment of obesity, primarily focusing on the prevention of obesity-related complications, particularly CVD. By applying these recommendations, healthcare professionals can tailor therapeutic strategies to the specific needs of individuals living with obesity. We hope that the widespread implementation of this guideline will contribute to reducing the adverse health burden of obesity and CVD, improving public health outcomes in Brazil.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-025-01954-8","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:54:27Z","timestamp":1763463267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["2025 Brazilian evidence-based guideline on the management of obesity and prevention of cardiovascular disease and obesity-associated complications: a position statement by five medical societies"],"prefix":"10.1186","volume":"17","author":[{"given":"Cynthia M.","family":"Valerio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F. K.","family":"Saraiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"van de Sande-Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane Z.","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana H.","family":"Rached","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano F.","family":"Drager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wellington S. Silva","family":"J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio R.","family":"Trujilho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neuton","family":"Dornelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruy Lyra","family":"da Silva Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Eduardo N.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo H. V.","family":"Assad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio C.","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo A. C.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo N.","family":"Lamounier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello C.","family":"Bertoluci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"1954_CR1","unstructured":"World Obesity Federation. World obesity. Atlas. London: World Obesity Federation. 2025.. https:\/\/data.worldobesity.org\/publications\/?cat=23 Accessed 2025 Jul 05"},{"key":"1954_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcaf022","author":"SCW Tan","year":"2025","unstructured":"Tan SCW, Zheng BB, Tang ML, Chu H, Zhao YT, Weng C. Global burden of cardiovascular diseases and its risk factors, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. QJM. 2025. https:\/\/doi.org\/10.1093\/qjmed\/hcaf022.","journal-title":"QJM"},{"key":"1954_CR3","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","volume":"45","author":"KC Koskinas","year":"2024","unstructured":"Koskinas KC, Van Craenenbroeck EM, Antoniades C, Bl\u00fcher M, Gorter TM, Hanssen H, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J. 2024;45:4063\u201398. https:\/\/doi.org\/10.1093\/eurheartj\/ehae508.","journal-title":"Eur Heart J"},{"key":"1954_CR4","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, Despr\u00e9s JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143:e984\u20131010. https:\/\/doi.org\/10.1161\/CIR.0000000000000973.","journal-title":"Circulation"},{"key":"1954_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.mayocp.2013.11.011","volume":"89","author":"JR Cerhan","year":"2014","unstructured":"Cerhan JR, Moore SC, Jacobs EJ, Kitahara CM, Rosenberg PS, Adami HO, et al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc. 2014;89:335\u201345. https:\/\/doi.org\/10.1016\/j.mayocp.2013.11.011.","journal-title":"Mayo Clin Proc"},{"key":"1954_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/ejcn.2013.61","volume":"67","author":"S Carmienke","year":"2013","unstructured":"Carmienke S, Freitag MH, Pischon T, Schlattmann P, Fankhaenel T, Goebel H, et al. General and abdominal obesity parameters, and their combination in relation to mortality: a systematic review and meta-regression analysis. Eur J Clin Nutr. 2013;67:573\u201385. https:\/\/doi.org\/10.1038\/ejcn.2013.61.","journal-title":"Eur J Clin Nutr"},{"key":"1954_CR7","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1093\/cvr\/cvab368","volume":"118","author":"M Benn","year":"2023","unstructured":"Benn M, Marott SCW, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Obesity increases heart failure incidence and mortality: observational and Mendelian randomization studies totalling over 1 million individuals. Cardiovasc Res. 2023;118:3576\u201385. https:\/\/doi.org\/10.1093\/cvr\/cvab368.","journal-title":"Cardiovasc Res"},{"key":"1954_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1089\/dtom.2025.0015","volume":"1","author":"WS Silva J\u00fanior","year":"2025","unstructured":"Silva J\u00fanior WS. Under new criteria for clinical obesity, is metabolic obesity with normal body weight finally a legitimate disease phenotype? Diabetes Technol Obes Med. 2025;1:62\u201370. https:\/\/doi.org\/10.1089\/dtom.2025.0015.","journal-title":"Diabetes Technol Obes Med"},{"key":"1954_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S2213-8587(23)00058-X","volume":"11","author":"F Rubino","year":"2023","unstructured":"Rubino F, Batterham RL, Koch M, Mingrone G, Le Roux CW, Farooqi IS, et al. Lancet diabetes & endocrinology commission on the definition and diagnosis of clinical obesity. Lancet Diabetes Endocrinol. 2023;11:226\u20138. https:\/\/doi.org\/10.1016\/S2213-8587(23)00058-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1954_CR10","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","volume":"30","author":"L Busetto","year":"2024","unstructured":"Busetto L, Dicker D, Fr\u00fchbeck G, Halford JCG, Sbraccia P, Yumuk V, et al. A new framework for the diagnosis, staging, and management of obesity in adults. Nat Med. 2024;30:2395\u20139. https:\/\/doi.org\/10.1038\/s41591-024-03095-3.","journal-title":"Nat Med"},{"key":"1954_CR11","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1111\/dom.16236","volume":"27","author":"XY Liu","year":"2025","unstructured":"Liu XY, Ge SY, Liu CA, Yin B, Bu ZT, Zheng X, et al. Validation of the 2024 European Association for the Study of Obesity diagnostic criteria: a comprehensive assessment of obesity-related mortality risks. Diabetes Obes Metab. 2025;27:2405\u201317. https:\/\/doi.org\/10.1111\/dom.16236.","journal-title":"Diabetes Obes Metab"},{"key":"1954_CR12","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13098-025-01796-4","volume":"17","author":"AF Godoy-Matos","year":"2025","unstructured":"Godoy-Matos AF, Val\u00e9rio CM, Silva J\u00fanior WS, de Araujo-Neto JM, Sposito AC, Suassuna JHR. Cardial-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome): a new proposition for an integrated multisystem metabolic disease. Diabetol Metab Syndr. 2025;17:218. https:\/\/doi.org\/10.1186\/s13098-025-01796-4, PMID:40524210,PMCID:PMC12168269.","journal-title":"Diabetol Metab Syndr"},{"issue":"11","key":"1954_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2023","unstructured":"Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and validation of the American Heart Association predicting risk of cardiovascular disease EVENTs (PREVENTTM) equations. Circulation. 2023;149(11):e956. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067626.","journal-title":"Circulation"},{"issue":"3","key":"1954_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-080891","volume":"14","author":"M Arici","year":"2024","unstructured":"Arici M, Assaad-Khalil SH, Bertoluci MC, Choo J, Lee YJ, Madero M, et al. Results from a cross-specialty consensus on optimal management of patients with chronic kidney disease (CKD): from screening to complications. BMJ Open. 2024;14(3):e080891. https:\/\/doi.org\/10.1136\/bmjopen-2023-080891.","journal-title":"BMJ Open"},{"key":"1954_CR15","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","volume":"148","author":"SS Khan","year":"2023","unstructured":"Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation. 2023;148:1982\u20132004. https:\/\/doi.org\/10.1161\/CIR.0000000000001191.","journal-title":"Circulation"},{"key":"1954_CR16","unstructured":"PREVENT online calculator \u2013 professional heart daily. American Heart Association"},{"key":"1954_CR17","first-page":"387","volume":"27","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal definition, and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. Japanese Heart Failure SocietyWriting Committee Univers Defin Heart Failure. 2021;27:387\u2013413.","journal-title":"Japanese Heart Failure SocietyWriting Committee Univers Defin Heart Failure."},{"key":"1954_CR18","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1038\/s41591-024-03140-1","volume":"30","author":"YNV Reddy","year":"2024","unstructured":"Reddy YNV, Carter RE, Sundaram V, Kaye DM, Handoko ML, Tedford RJ, et al. An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score. Nat Med. 2024;30:2258\u201364. https:\/\/doi.org\/10.1038\/s41591-024-03140-1.","journal-title":"Nat Med"},{"issue":"3","key":"1954_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ijcard.2013.08.088","volume":"169","author":"X Wang","year":"2013","unstructured":"Wang X, Ouyang Y, Wang Z, Zhao G, Liu L, Bi Y. Obstructive sleep apnea and risk of cardiovascular disease and all-cause mortality: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013;169(3):207\u201314. https:\/\/doi.org\/10.1016\/j.ijcard.2013.08.088.","journal-title":"Int J Cardiol"},{"key":"1954_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.sleep.2020.03.011","volume":"71","author":"X Zhang","year":"2020","unstructured":"Zhang X, Fan J, Guo Y, Zhou J, Chen F, Jin Z, et al. Association between obstructive sleep apnoea syndrome and the risk of cardiovascular diseases: an updated systematic review and dose-response meta-analysis. Sleep Med. 2020;71:39\u201346. https:\/\/doi.org\/10.1016\/j.sleep.2020.03.011.","journal-title":"Sleep Med"},{"key":"1954_CR21","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1161\/CIRCULATIONAHA.124.072156","volume":"151","author":"YNV Reddy","year":"2025","unstructured":"Reddy YNV, Tada A, Obokata M, Carter RE, Kaye DM, Handoko ML, et al. Evidence-based application of natriuretic peptides in the evaluation of chronic heart failure with preserved ejection fraction in the ambulatory outpatient setting. Circulation. 2025;151:976\u201389. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072156.","journal-title":"Circulation"},{"key":"1954_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman R, Lacin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393\u2013403. https:\/\/doi.org\/10.1056\/NEJMoa012512.","journal-title":"N Engl J Med"},{"issue":"2","key":"1954_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"RR Wing","year":"2013","unstructured":"Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1212914.","journal-title":"N Engl J Med"},{"key":"1954_CR24","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481\u20136. https:\/\/doi.org\/10.2337\/dc10-2415.","journal-title":"Diabetes Care"},{"key":"1954_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S2213-8587(19)30093-2","volume":"7","author":"Q Gong","year":"2019","unstructured":"Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7:452\u201361. https:\/\/doi.org\/10.1016\/S2213-8587(19)30093-2.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1954_CR26","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.2337\/dc21-1805","volume":"45","author":"RR Wing","year":"2022","unstructured":"Wing RR, Bray GA, Cassidy-Begay M, Clark JM, Coday M, Egan C, et al. Effects of intensive lifestyle intervention on all-cause mortality in older adults with type 2 diabetes and overweight\/obesity: results from the Look AHEAD study. Diabetes Care. 2022;45:1252\u20139. https:\/\/doi.org\/10.2337\/dc21-1805.","journal-title":"Diabetes Care"},{"key":"1954_CR27","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","volume":"4","author":"Look AHEAD Research Group","year":"2016","unstructured":"Look AHEAD Research Group. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4:913\u201321.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1954_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S2213-8587(24)00363-2","volume":"13","author":"N Sattar","year":"2025","unstructured":"Sattar N, Lee MMY. Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions. Lancet Diabetes Endocrinol. 2025;13(4):347\u201354. https:\/\/doi.org\/10.1016\/S2213-8587(24)00363-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1954_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.2011.1914","volume":"307","author":"L Sj\u00f6str\u00f6m","year":"2012","unstructured":"Sj\u00f6str\u00f6m L, Peltonen M, Jacobson P, Sj\u00f6str\u00f6m CD, Karason K, Wedel H, et al. Bariatric surgery, and long-term cardiovascular events. JAMA. 2012;307(1):56\u201365. https:\/\/doi.org\/10.1001\/jama.2011.1914.","journal-title":"JAMA"},{"key":"1954_CR30","doi-asserted-by":"publisher","unstructured":"Halpern B, Mancini MC, de Melo ME, Lamounier RN, Moreira RO, Carra MK, et al. Proposal of an obesity classification based on weight history: an official document by the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society for the Study of Obesity and Metabolic Syndrome (ABESO). Arch Endocrinol Metab.;66:139\u201351. https:\/\/doi.org\/10.20945\/2359-3997000000465 2022","DOI":"10.20945\/2359-3997000000465"},{"issue":"20","key":"1954_CR31","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/eurheartj\/ehv486","volume":"37","author":"CJ Nalliah","year":"2016","unstructured":"Nalliah CJ, Sanders P, Kottkamp H, Kalman JM. The role of obesity in atrial fibrillation. Eur Heart J. 2016;37(20):1565\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehv486.","journal-title":"Eur Heart J"},{"key":"1954_CR32","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1001\/jama.2013.280521","volume":"310","author":"HS Abed","year":"2013","unstructured":"Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050\u201360. https:\/\/doi.org\/10.1001\/jama.2013.280521.","journal-title":"JAMA"},{"key":"1954_CR33","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.amjcard.2019.08.009","volume":"124","author":"OM Aldaas","year":"2019","unstructured":"Aldaas OM, Lupercio F, Han FT, Hoffmayer KS, Krummen D, Ho G, et al. Meta-analysis of effect of modest (\u226510%) weight loss in management of overweight and obese patients with atrial fibrillation. Am J Cardiol. 2019;124:1568\u201374. https:\/\/doi.org\/10.1016\/j.amjcard.2019.08.009.","journal-title":"Am J Cardiol"},{"key":"1954_CR34","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1111\/jce.16090","volume":"34","author":"KH Akhtar","year":"2023","unstructured":"Akhtar KH, Jafry AH, Beard C, Nasir YM, Agarwal S, Khan J, et al. The effect of weight loss on recurrence of atrial fibrillation after catheter ablation: a systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2023;34:2514\u201326. https:\/\/doi.org\/10.1111\/jce.16090.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1954_CR35","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.jacc.2016.09.940","volume":"68","author":"S Jamaly","year":"2016","unstructured":"Jamaly S, Carlsson L, Peltonen M, Jacobson P, Sj\u00f6str\u00f6m L, Karason K. Bariatric surgery and the risk of new-onset atrial fibrillation in Swedish obese subjects. J Am Coll Cardiol. 2016;68:2497\u2013504. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.940.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1037\/amp0000517","volume":"75","author":"TA Wadden","year":"2020","unstructured":"Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75:235\u201351. https:\/\/doi.org\/10.1037\/amp0000517.","journal-title":"Am Psychol"},{"key":"1954_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/dom.14200","volume":"23","author":"GA Bray","year":"2021","unstructured":"Bray GA, Ryan DH. Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes. Diabetes Obes Metab. 2021;23:50\u201362. https:\/\/doi.org\/10.1111\/dom.14200.","journal-title":"Diabetes Obes Metab"},{"key":"1954_CR38","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1056\/NEJMoa050156","volume":"353","author":"TA Wadden","year":"2005","unstructured":"Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111\u201320. https:\/\/doi.org\/10.1056\/NEJMoa050156.","journal-title":"N Engl J Med"},{"key":"1954_CR39","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","volume":"384","author":"JR Lundgren","year":"2021","unstructured":"Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384:1719\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2028198.","journal-title":"N Engl J Med"},{"key":"1954_CR40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O\u2019Neil PM, et al. Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19:110\u201320. https:\/\/doi.org\/10.1038\/oby.2010.147.","journal-title":"Obesity"},{"issue":"14","key":"1954_CR41","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs. placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313. https:\/\/doi.org\/10.1001\/jama.2021.1831.","journal-title":"JAMA"},{"key":"1954_CR42","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29:2909\u201318. https:\/\/doi.org\/10.1038\/s41591-023-02597-w.","journal-title":"Nat Med"},{"issue":"4","key":"1954_CR43","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s13679-023-00534-z","volume":"12","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Moore M, Tronieri JS, Gilden A, Amaro A, et al. The role of lifestyle modification with second-generation anti-obesity medications: comparisons, questions, and clinical opportunities. Curr Obes Rep. 2023;12(4):453\u201373. https:\/\/doi.org\/10.1007\/s13679-023-00534-z.","journal-title":"Curr Obes Rep"},{"key":"1954_CR44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800389","volume":"378","author":"R Estruch","year":"2018","unstructured":"Estruch R, Ros E, Salas-Salvad\u00f3 J, Covas MI, Corella D, Ar\u00f3s F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378:e34. https:\/\/doi.org\/10.1056\/NEJMoa1800389.","journal-title":"N Engl J Med"},{"issue":"2","key":"1954_CR45","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jamainternmed.2022.6117","volume":"183","author":"Z Shan","year":"2023","unstructured":"Shan Z, Wang F, Li Y, Baden MY, Bhupathiraju SN, Wang DD, et al. Healthy eating patterns and risk of total and cause-specific mortality. JAMA Intern Med. 2023;183(2):142\u201353. https:\/\/doi.org\/10.1001\/jamainternmed.2022.6117.","journal-title":"JAMA Intern Med"},{"key":"1954_CR46","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13098-023-01037-6","volume":"15","author":"RB Pepe","year":"2023","unstructured":"Pepe RB, Lottenberg AM, Fujiwara CTH, Beyruti M, Cintra DE, Machado RM, et al. Position statement on nutrition therapy for overweight and obesity: nutrition department of the Brazilian association for the study of obesity and metabolic syndrome (ABESO-2022). Diabetol Metab Syndr. 2023;15:124. https:\/\/doi.org\/10.1186\/s13098-023-01037-6.","journal-title":"Diabetol Metab Syndr"},{"issue":"68","key":"1954_CR47","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.amepre.2025.02.018","volume":"S07493797250007","author":"EAF Nilson","year":"2025","unstructured":"Nilson EAF, Delpino FM, Batis C, Machado PP, Moubarac JC, Cediel G, et al. Premature mortality attributable to ultraprocessed food consumption in eight countries. Am J Prev Med. 2025;S0749379725000728(68):1091\u20139. https:\/\/doi.org\/10.1016\/j.amepre.2025.02.018.","journal-title":"Am J Prev Med"},{"key":"1954_CR48","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/S0140-6736(17)30705-5","volume":"389","author":"CW Le Roux","year":"2017","unstructured":"Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DC, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial [published correction appears in Lancet. Lancet. 2017;389:1398. https:\/\/doi.org\/10.1016\/S0140-6736(17)30705-5.","journal-title":"Lancet"},{"key":"1954_CR49","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/dom.13125","volume":"20","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018;20:734\u20139. https:\/\/doi.org\/10.1111\/dom.13125.","journal-title":"Diabetes Obes Metab"},{"key":"1954_CR50","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"key":"1954_CR51","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, Le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392:958\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2410819.","journal-title":"N Engl J Med"},{"key":"1954_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105782","volume":"171","author":"E Lazzaroni","year":"2021","unstructured":"Lazzaroni E, Ben Nasr M, Loretelli C, Pastore I, Plebani L, Lunati ME, et al. Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res. 2021;171:105782. https:\/\/doi.org\/10.1016\/j.phrs.2021.105782.","journal-title":"Pharmacol Res"},{"key":"1954_CR53","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sj\u00f6str\u00f6m L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155\u201361. https:\/\/doi.org\/10.2337\/diacare.27.1.155.","journal-title":"Diabetes Care"},{"key":"1954_CR54","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1001\/jama.2016.7602","volume":"315","author":"R Khera","year":"2016","unstructured":"Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315:2424\u201334. https:\/\/doi.org\/10.1001\/jama.2016.7602.","journal-title":"JAMA"},{"key":"1954_CR55","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1053\/j.gastro.2017.12.024","volume":"154","author":"R Khera","year":"2018","unstructured":"Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, et al. Effects of weight-loss medications on cardiometabolic risk profiles: A systematic review and network meta-analysis. Gastroenterol. 2018;154:1309\u201319. https:\/\/doi.org\/10.1053\/j.gastro.2017.12.024.","journal-title":"Gastroenterol"},{"key":"1954_CR56","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jama.2016.1558","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315:990\u20131004. https:\/\/doi.org\/10.1001\/jama.2016.1558.","journal-title":"JAMA"},{"key":"1954_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13224","volume":"22","author":"AC Sposito","year":"2021","unstructured":"Sposito AC, Bonilha I, Luchiari B, Benchimol A, Hohl A, Moura F, et al. Cardiovascular safety of naltrexone and bupropion therapy: systematic review and meta-analyses. Obes Rev. 2021;22:e13224. https:\/\/doi.org\/10.1111\/obr.13224.","journal-title":"Obes Rev"},{"issue":"1\u201336","key":"1954_CR58","doi-asserted-by":"publisher","DOI":"10.20945\/2359-4292-2024-0422","volume":"68","author":"RO Moreira","year":"2024","unstructured":"Moreira RO, Valerio CM, Hohl A, Moulin C, Moura F, Trujilho FR, et al. Pharmacologic treatment of obesity in adults and its impact on comorbidities: 2024 update and position statement of specialists from the Brazilian association for the study of obesity and metabolic syndrome (Abeso) and the Brazilian society of Endocrinology and Metabolism (SBEM). Arch Endocrinol Metab. 2024;68(1\u201336):e240422.https:\/\/doi.org\/10.20945\/2359-4292-2024-0422","journal-title":"Arch Endocrinol Metab"},{"key":"1954_CR59","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"key":"1954_CR60","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa1003114","volume":"363","author":"WPT James","year":"2010","unstructured":"James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1003114.","journal-title":"N Engl J Med"},{"issue":"3","key":"1954_CR61","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2337\/dc24-1533","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee MMY, Ghouri N, Misra A, Kang YM, Rutter MK, Gerstein HC, et al. Comparative efficacy of glucagon-like peptide 1 receptor agonists for cardiovascular outcomes in Asian versus White populations: systematic review and meta-analysis of randomized trials of populations with or without type 2 diabetes and\/or overweight or obesity. Diabetes Care. 2025;48(3):489\u201393. https:\/\/doi.org\/10.2337\/dc24-1533.","journal-title":"Diabetes Care"},{"key":"1954_CR62","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1954_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. https:\/\/doi.org\/10.1136\/bmj.m4573.","journal-title":"BMJ"},{"issue":"20","key":"1954_CR64","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2501006.","journal-title":"N Engl J Med"},{"key":"1954_CR65","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"4","key":"1954_CR66","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1164\/rccm.200805-669OC","volume":"179","author":"HPI Tuomilehto","year":"2009","unstructured":"Tuomilehto HPI, Sepp\u00e4 JM, Partinen MM, Peltonen M, Gylling H, Tuomilehto JOI, et al. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med. 2009;179(4):320\u20137. https:\/\/doi.org\/10.1164\/rccm.200805-669OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1954_CR67","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1001\/archinternmed.2009.266","volume":"169","author":"GD Foster","year":"2009","unstructured":"Foster GD, Borradaile KE, Sanders MH, Millman R, Zammit G, Newman AB, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169:1619\u201326. https:\/\/doi.org\/10.1001\/archinternmed.2009.266, PMCID:PMC2879275.","journal-title":"Arch Intern Med"},{"issue":"4","key":"1954_CR68","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.8212","volume":"5","author":"A Carneiro-Barrera","year":"2022","unstructured":"Carneiro-Barrera A, Amaro-Gahete FJ, Guill\u00e9n-Riquelme A, Jurado-Fasoli L, S\u00e1ez-Roca G, Mart\u00edn-Carrasco C, et al. Effect of an interdisciplinary weight loss and lifestyle intervention on obstructive sleep apnea severity: the INTERAPNEA randomized clinical trial. JAMA Netw Open. 2022;5(4):e228212. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.8212.","journal-title":"JAMA Netw Open"},{"key":"1954_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4609","volume":"339","author":"K Johansson","year":"2009","unstructured":"Johansson K, Neovius M, Lagerros YT, Harlid R, R\u00f6ssner S, Granath F, et al. Effect of a very low energy diet on moderate and severe obstructive sleep apnoea in obese men: a randomised controlled trial. BMJ. 2009;339:b4609. https:\/\/doi.org\/10.1136\/bmj.b4609.","journal-title":"BMJ"},{"key":"1954_CR70","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond). 2016;40:1310\u20139. https:\/\/doi.org\/10.1038\/ijo.2016.52.","journal-title":"Int J Obes (Lond)"},{"key":"1954_CR71","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391:1193\u2013205. https:\/\/doi.org\/10.1056\/NEJMoa2404881.","journal-title":"N Engl J Med"},{"key":"1954_CR72","unstructured":"FDA Approves First Medication for Obstructive Sleep Apnea. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-medication-obstructive-sleep-apnea. Accessed 12\/20\/ 2024"},{"key":"1954_CR73","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1513\/AnnalsATS.202101-060OC","volume":"18","author":"B Chen","year":"2021","unstructured":"Chen B, Drager LF, Peker Y, Vgontzas AN, Phillips CL, Hoyos CM, et al. Effect of continuous positive airway pressure on weight and local adiposity in adults with obstructive sleep apnea: a meta-analysis. Ann Am Thorac Soc. 2021;18:1717\u201327. https:\/\/doi.org\/10.1513\/AnnalsATS.202101-060OC.","journal-title":"Ann Am Thorac Soc"},{"key":"1954_CR74","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/eurjpc\/zwad284","volume":"30","author":"M Chi","year":"2023","unstructured":"Chi M, Nie Y, Su Y, Wang N, Li A, Ma T, et al. Effects of weight loss in heart failure patients with overweight and obesity: a systematic review and meta-analysis. Eur J Prev Cardiol. 2023;30:1906\u201321. https:\/\/doi.org\/10.1093\/eurjpc\/zwad284. (PMID: 37652032).","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"1954_CR75","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/heartjnl-2019-314770","volume":"106","author":"R Mahajan","year":"2020","unstructured":"Mahajan R, Stokes M, Elliott A, Munawar DA, Khokhar KB, Thiyagarajah A, et al. Complex interaction of obesity, intentional weight loss and heart failure: a systematic review and meta-analysis. Heart. 2020;106(1):58\u201368. https:\/\/doi.org\/10.1136\/heartjnl-2019-314770.","journal-title":"Heart"},{"key":"1954_CR76","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963.","journal-title":"N Engl J Med"},{"key":"1954_CR77","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jchf.2023.05.010","volume":"11","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Christensen L, Davies M, et al. Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype. JACC Heart Fail. 2023;11:1000\u201310. https:\/\/doi.org\/10.1016\/j.jchf.2023.05.010.","journal-title":"JACC Heart Fail"},{"key":"1954_CR78","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392:427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"key":"1954_CR79","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(22)01429-5.","journal-title":"Lancet"},{"issue":"5","key":"1954_CR80","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500\u20138. https:\/\/doi.org\/10.1001\/jama.2016.10260.","journal-title":"JAMA"},{"issue":"6","key":"1954_CR81","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/ehf2.12334","volume":"5","author":"A Sharma","year":"2018","unstructured":"Sharma A, Ambrosy AP, Devore AD, Margulies KB, McNulty SE, Mentz RJ, et al. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Fail. 2018;5(6):1035\u201343. https:\/\/doi.org\/10.1002\/ehf2.12334.","journal-title":"ESC Heart Fail"},{"key":"1954_CR82","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, H\u00e4nselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) \u2013 a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19:69\u201377. https:\/\/doi.org\/10.1002\/ejhf.657.","journal-title":"Eur J Heart Fail"},{"key":"1954_CR83","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","volume":"404","author":"J Deanfield","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404:773\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(24)01498-3.","journal-title":"Lancet"},{"key":"1954_CR84","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.jacc.2023.09.811","volume":"82","author":"J Butler","year":"2023","unstructured":"Butler J, Abildstr\u00f8m SZ, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, et al. Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction. J Am Coll Cardiol. 2023;82:2087\u201396. https:\/\/doi.org\/10.1016\/j.jacc.2023.09.811.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR85","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","volume":"110","author":"F Sun","year":"2015","unstructured":"Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110:26\u201337. https:\/\/doi.org\/10.1016\/j.diabres.2015.07.015.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"1954_CR86","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/dom.16078","volume":"27","author":"M Zhang","year":"2025","unstructured":"Zhang M, Lin C, Cai X, Jiao R, Bai S, Li Z, et al. One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA. Diabetes Obes Metab. 2025;27(2):806\u201315. https:\/\/doi.org\/10.1111\/dom.16078.","journal-title":"Diabetes Obes Metab"},{"key":"1954_CR87","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.amjmed.2024.04.032","volume":"137","author":"D Garc\u00eda-Vega","year":"2024","unstructured":"Garc\u00eda-Vega D, Cinza-Sanjurjo S, Eiras S, Gonz\u00e1lez-Juanatey JR. Combined sodium-glucose-transporters inhibitors and glucagon-like-peptide receptor agonist compared with monotherapy improves long-term survival: a real-world registry. Am J Med. 2024;137:761\u2013769.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2024.04.032.","journal-title":"Am J Med"},{"key":"1954_CR88","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1237","volume":"385","author":"N Simms-Williams","year":"2024","unstructured":"Simms-Williams N, Treves N, Yin H, Lu S, Yu O, Pradhan R, et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population-based cohort study. BMJ. 2024;385:e078242. https:\/\/doi.org\/10.1136\/bmj.q1237.","journal-title":"BMJ"},{"key":"1954_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003206","volume":"17","author":"T Wiggins","year":"2020","unstructured":"Wiggins T, Guidozzi N, Welbourn R, Ahmed AR, Markar SR. Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: a systematic review and meta-analysis. PLoS Med. 2020;17:e1003206. https:\/\/doi.org\/10.1371\/journal.pmed.1003206.","journal-title":"PLoS Med"},{"issue":"5","key":"1954_CR90","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005126","volume":"6","author":"PN Benotti","year":"2017","unstructured":"Benotti PN, Wood GC, Carey DJ, Mehra VC, Mirshahi T, Lent MR, et al. Gastric bypass surgery produces a durable reduction in cardiovascular disease risk factors and reduces the long-term risks of congestive heart failure. J Am Heart Assoc. 2017;6(5):e005126. https:\/\/doi.org\/10.1161\/JAHA.116.005126.","journal-title":"J Am Heart Assoc"},{"key":"1954_CR91","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1001\/jama.2018.14619","volume":"320","author":"DP Fisher","year":"2018","unstructured":"Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O\u2019Connor PJ, et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA. 2018;320:1570\u201382. https:\/\/doi.org\/10.1001\/jama.2018.14619.","journal-title":"JAMA"},{"key":"1954_CR92","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/eurheartj\/ehz295","volume":"40","author":"S Jamaly","year":"2019","unstructured":"Jamaly S, Carlsson L, Peltonen M, Jacobson P, Karason K. Surgical obesity treatment and the risk of heart failure. Eur Heart J. 2019;40:2131\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehz295.","journal-title":"Eur Heart J"},{"key":"1954_CR93","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1007\/s11695-023-06898-4","volume":"33","author":"A Esparham","year":"2023","unstructured":"Esparham A, Mehri A, Hadian H, Taheri M, Anari Moghadam H, Kalantari A, et al. The effect of bariatric surgery on patients with heart failure: a systematic review and meta-analysis. Obes Surg. 2023;33:4125\u201336. https:\/\/doi.org\/10.1007\/s11695-023-06898-4.","journal-title":"Obes Surg"},{"key":"1954_CR94","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.surg.2021.04.036","volume":"170","author":"TL Kindel","year":"2021","unstructured":"Kindel TL, Higgins RM, Lak K, Gould J, Baumann Kreuziger L, Mohammed A, et al. Bariatric surgery in patients with advanced heart failure: a proposed multi-disciplinary pathway for surgical care in medically complex patients. Surgery. 2021;170:659\u201363. https:\/\/doi.org\/10.1016\/j.surg.2021.04.036.","journal-title":"Surgery"},{"issue":"1","key":"1954_CR95","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13300-024-01659-7","volume":"16","author":"SC Bain","year":"2025","unstructured":"Bain SC, Belmar N, Hoff ST, Husain M, Rasmussen S, Vilsb\u00f8ll T, et al. Cardiovascular, metabolic, and safety outcomes with semaglutide by baseline age: post hoc analysis of SUSTAIN 6 and PIONEER 6. Diabetes Ther. 2025;16(1):15\u201328. https:\/\/doi.org\/10.1007\/s13300-024-01659-7.","journal-title":"Diabetes Ther"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01954-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T23:03:18Z","timestamp":1763506998000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-025-01954-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1954"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01954-8","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate."}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CMV has received speaker and consultancy fees from Chiesi Pharmaceuticals, Eli Lilly, Merck, BI-Lilly, EMS, Abbvie and Novo Nordisk.JFKS has received speaker and consultancy fees from Astra Zeneca. Lilly, Novo Nordisk, Mantecorp, Bayer, Novartis, Daichii Sankyo, Boehringer Ingelheim, and MSD.FV has received speaker and consultancy fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, EMS, GSK, and Novo Nordisk.SvLS has received speaker and consultancy fees from Abbott, Lilly, and Merck e Novo Nordisk.VZR has received speaker and consultancy fees Abbott, Ach\u00e9, Daichii-Sankyo, Lilly, Novo Nordisk, Novartis, and Ultragenyx.FHR has received speaker and consultancy fees from Novartis, Novo Nordisk, and Daichii Sankyo.LFD has received speaker and consultancy fees from Lilly, Novo Nordisk, Astrazeneca, Boehringer, and ResMed.BH has received speaker and consultancy fees from Novo Nordisk, Lilly, Boehringer Ingelheim, Astra Zeneca, Merck, and Novartis.WSSJ has received speaker and consultancy fees from Abbott, AstraZeneca, Brace Pharma, Libbs, Lilly, Novartis, Novo Nordisk, and Roche.FRT has received speaker and consultancy fees from Ach\u00e9, AstraZeneca, Chiesi, BracePharma, Boehringer Ingelheim and Eli Lilly do Brasil, EMS, Eurofarma, Johnson & Johnson, Myrallis, Merck, Novo Nordisk, Servier, Scitech Medical, and Takeda.ND has received speaker and consultancy fees from Novo Nordisk.RLSF has received speaker and consultancy fees from Astra Zeneca. Lilly, Novo Nordisk, Boheringer, Mantecorp, Biolab, Brace Farma, EMS and Eurofarma.JENS has received speaker and consultancy fees from Astrazeneca, Bayer, Boehringer-Ingelheim, Lilly, Merck serono, and Novo Nordisk.MHVA has received speaker and consultancy fees from Astrazeneca, Bayer, Biolab, Daiichi Sankyo, EMS, GSK, Novartis, Novo Nordisk, and Lilly.MM has received speaker and consultancy fees from Lilly, Merck, EMS, Eurofarma, Myralis, and Brace Farma.PACM has received speaker and consultancy fees from NovoNordisk, Lilly, Recordat, Ache, and Ipsen.ROM has received speaker and consultancy fees from Astra-Zeneca, Merck, Bayer, Libbs, EMC, Brace Pharma, Servier, PTC, Lilly, and NovoNordisk.RNL has received speaker and consultancy fees from Abbott, Astra Zeneca, Eli Lilly, Medtronic, and Novo Nordisk.SK has received speaker and consultancy fees from Bayer, Biolab, Novo Nordisk, Novartis, Astrazeneca, Farmoquimica, and Daiichi Sankyo.MCB has received speaker and consultancy fees from Amgen, Bayer, Daiichi Sankyo, Eli-Lilly, Astrazeneca and Novo Nordisk.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}